AstraZeneca flop a fresh blow to cancer immunotherapy combination [Reuters (UK)]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Reuters
AstraZeneca flop a fresh blow to cancer immunotherapy combination | Reuters 4 Min Read LONDON (Reuters) - The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study. Adding the company’s experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday. Shares in AstraZeneca fell 1 percent following the news. The result of the study, known as ARCTIC, is disappointing but not a huge surprise, since evidence has been building that there may be little value in using a so-called CTLA-4 drug like tremelimumab on top of a PD-L1 such as Imfinzi. Indeed, since Imfinzi on its own showed some signs of efficacy, whereas adding tremelimumab did not, analysts believe the second drug might actually offset
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- ICH Q9 (R1) Quality Risk Management (QRM) Training Course (ONLINE EVENT) [Yahoo! Finance]Yahoo! Finance
- Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency" [Yahoo! Finance]Yahoo! Finance
- Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer [Yahoo! Finance]Yahoo! Finance
- AstraZeneca PLC (NASDAQ: AZN) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "hold" rating.MarketBeat
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/11/24 - Form 6-K
- 4/11/24 - Form 6-K
- 4/8/24 - Form 6-K
- AZN's page on the SEC website